Comparison of buprenorphine and methadone in the treatment of opioid dependence
OBJECTIVE: This study compared the efficacy of buprenorphine and methadone in the treatment of opioid dependence. METHOD: Participants (N = 164) were relatively treatment-naive, opioid-dependent applicants to a 26-week treatment program who were randomly assigned to either methadone or buprenorphine...
Gespeichert in:
| Veröffentlicht in: | The American journal of psychiatry 1994-07, Vol.151 (7), p.1025-1030 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1030 |
|---|---|
| container_issue | 7 |
| container_start_page | 1025 |
| container_title | The American journal of psychiatry |
| container_volume | 151 |
| creator | STRAIN, E. C STITZER, M. L LIEBSON, I. A BIGELOW, G. E |
| description | OBJECTIVE: This study compared the efficacy of buprenorphine and
methadone in the treatment of opioid dependence. METHOD: Participants (N =
164) were relatively treatment-naive, opioid-dependent applicants to a
26-week treatment program who were randomly assigned to either methadone or
buprenorphine treatment. Dosing was double-blind and double-dummy. Patients
were stabilized on a regimen of either methadone, 50 mg, or buprenorphine,
8 mg, with dose changes possible through week 16 of treatment. Urine
samples were collected three times a week, and weekly counseling was
provided. RESULTS: Buprenorphine (mean dose = 8.9 mg/day) and methadone
(mean dose = 54 mg/day) were equally effective in sustaining retention in
treatment, compliance with medication, and counseling regimens. In both
groups, 56% of patients remained in treatment through the 16-week flexible
dosing period. Overall opioid-positive urine sample rates were 55% and 47%
for buprenorphine and methadone groups, respectively; cocaine-positive
urine sample rates were 70% and 58%. Evidence was obtained for the
effectiveness of dose increases in suppressing opioid, but not cocaine, use
among those who received dose increases. CONCLUSIONS: The results of this
study provide further support for the utility of buprenorphine as a new
medication in the treatment of opioid dependence and demonstrate efficacy
equivalent to that of methadone when used during a clinically guided
flexible dosing procedure. |
| doi_str_mv | 10.1176/ajp.151.7.1025 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_220458119</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1310625327</sourcerecordid><originalsourceid>FETCH-LOGICAL-a434t-ec7d161b6308eb192b2361a591ba27e284a53299f28312eb3a9053d1fb2ca3b23</originalsourceid><addsrcrecordid>eNp1kEFr3DAQRkVo2G42ueZWME1vxa5GsmzrGJY0DQT2kkBvYmyPWS9rSZW8h_z7aNkl9NCehmHezDc8xm6BFwB19QN3vgAFRV0AF-qCLUFJlddCNJ_YknMucq3k78_sKsZdarmsxYItGg5cKr1km7WbPIYxOpu5IWsPPpB1wW9HSxnaPpto3mLvUjfabN5SNgfCeSI7H3nnRzf2WU-ebE-2o2t2OeA-0s25rtjrz4eX9a_8efP4tL5_zrGU5ZxTV_dQQVtJ3lALWrRCVoBKQ4uiJtGUqKTQehCNBEGtRM2V7GFoRYcywSv29XTXB_fnQHE2O3cINkUaIXipGgCdoLv_QSCBVyJl1IkqTlQXXIyBBuPDOGF4M8DN0bFJjk1ybGpzdJwWvpzPHtqJ-g_8LDXNv53nGDvcDwFtN8YPrIRKc33M_X7C0Pvxr8_-HfoOUQKQbA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1310625327</pqid></control><display><type>article</type><title>Comparison of buprenorphine and methadone in the treatment of opioid dependence</title><source>MEDLINE</source><source>Psychiatry Legacy Collection Online Journals 1844-1996</source><source>Periodicals Index Online</source><creator>STRAIN, E. C ; STITZER, M. L ; LIEBSON, I. A ; BIGELOW, G. E</creator><creatorcontrib>STRAIN, E. C ; STITZER, M. L ; LIEBSON, I. A ; BIGELOW, G. E</creatorcontrib><description>OBJECTIVE: This study compared the efficacy of buprenorphine and
methadone in the treatment of opioid dependence. METHOD: Participants (N =
164) were relatively treatment-naive, opioid-dependent applicants to a
26-week treatment program who were randomly assigned to either methadone or
buprenorphine treatment. Dosing was double-blind and double-dummy. Patients
were stabilized on a regimen of either methadone, 50 mg, or buprenorphine,
8 mg, with dose changes possible through week 16 of treatment. Urine
samples were collected three times a week, and weekly counseling was
provided. RESULTS: Buprenorphine (mean dose = 8.9 mg/day) and methadone
(mean dose = 54 mg/day) were equally effective in sustaining retention in
treatment, compliance with medication, and counseling regimens. In both
groups, 56% of patients remained in treatment through the 16-week flexible
dosing period. Overall opioid-positive urine sample rates were 55% and 47%
for buprenorphine and methadone groups, respectively; cocaine-positive
urine sample rates were 70% and 58%. Evidence was obtained for the
effectiveness of dose increases in suppressing opioid, but not cocaine, use
among those who received dose increases. CONCLUSIONS: The results of this
study provide further support for the utility of buprenorphine as a new
medication in the treatment of opioid dependence and demonstrate efficacy
equivalent to that of methadone when used during a clinically guided
flexible dosing procedure.</description><identifier>ISSN: 0002-953X</identifier><identifier>EISSN: 1535-7228</identifier><identifier>DOI: 10.1176/ajp.151.7.1025</identifier><identifier>PMID: 8010359</identifier><identifier>CODEN: AJPSAO</identifier><language>eng</language><publisher>Washington, DC: American Psychiatric Publishing</publisher><subject>Administration, Oral ; Administration, Sublingual ; Adult ; Biological and medical sciences ; Buprenorphine - administration & dosage ; Buprenorphine - therapeutic use ; Cocaine - urine ; Comorbidity ; Double-Blind Method ; Drug addictions ; Drug therapy ; Female ; Heroin ; Humans ; Male ; Medical sciences ; Methadone - administration & dosage ; Methadone - therapeutic use ; Middle Aged ; Opioid-Related Disorders - drug therapy ; Opioid-Related Disorders - epidemiology ; Opioid-Related Disorders - rehabilitation ; Patient Compliance ; Psychiatry ; Substance Abuse Detection ; Substance abuse treatment ; Substance-Related Disorders - epidemiology ; Substance-Related Disorders - urine ; Toxicology ; Treatment Outcome</subject><ispartof>The American journal of psychiatry, 1994-07, Vol.151 (7), p.1025-1030</ispartof><rights>1994 INIST-CNRS</rights><rights>Copyright American Psychiatric Association Jul 1994</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a434t-ec7d161b6308eb192b2361a591ba27e284a53299f28312eb3a9053d1fb2ca3b23</citedby><cites>FETCH-LOGICAL-a434t-ec7d161b6308eb192b2361a591ba27e284a53299f28312eb3a9053d1fb2ca3b23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/ajp.151.7.1025$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/ajp.151.7.1025$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,2846,21608,23909,23910,25118,27846,27901,27902,77533,77534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4169097$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8010359$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>STRAIN, E. C</creatorcontrib><creatorcontrib>STITZER, M. L</creatorcontrib><creatorcontrib>LIEBSON, I. A</creatorcontrib><creatorcontrib>BIGELOW, G. E</creatorcontrib><title>Comparison of buprenorphine and methadone in the treatment of opioid dependence</title><title>The American journal of psychiatry</title><addtitle>Am J Psychiatry</addtitle><description>OBJECTIVE: This study compared the efficacy of buprenorphine and
methadone in the treatment of opioid dependence. METHOD: Participants (N =
164) were relatively treatment-naive, opioid-dependent applicants to a
26-week treatment program who were randomly assigned to either methadone or
buprenorphine treatment. Dosing was double-blind and double-dummy. Patients
were stabilized on a regimen of either methadone, 50 mg, or buprenorphine,
8 mg, with dose changes possible through week 16 of treatment. Urine
samples were collected three times a week, and weekly counseling was
provided. RESULTS: Buprenorphine (mean dose = 8.9 mg/day) and methadone
(mean dose = 54 mg/day) were equally effective in sustaining retention in
treatment, compliance with medication, and counseling regimens. In both
groups, 56% of patients remained in treatment through the 16-week flexible
dosing period. Overall opioid-positive urine sample rates were 55% and 47%
for buprenorphine and methadone groups, respectively; cocaine-positive
urine sample rates were 70% and 58%. Evidence was obtained for the
effectiveness of dose increases in suppressing opioid, but not cocaine, use
among those who received dose increases. CONCLUSIONS: The results of this
study provide further support for the utility of buprenorphine as a new
medication in the treatment of opioid dependence and demonstrate efficacy
equivalent to that of methadone when used during a clinically guided
flexible dosing procedure.</description><subject>Administration, Oral</subject><subject>Administration, Sublingual</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Buprenorphine - administration & dosage</subject><subject>Buprenorphine - therapeutic use</subject><subject>Cocaine - urine</subject><subject>Comorbidity</subject><subject>Double-Blind Method</subject><subject>Drug addictions</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Heroin</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methadone - administration & dosage</subject><subject>Methadone - therapeutic use</subject><subject>Middle Aged</subject><subject>Opioid-Related Disorders - drug therapy</subject><subject>Opioid-Related Disorders - epidemiology</subject><subject>Opioid-Related Disorders - rehabilitation</subject><subject>Patient Compliance</subject><subject>Psychiatry</subject><subject>Substance Abuse Detection</subject><subject>Substance abuse treatment</subject><subject>Substance-Related Disorders - epidemiology</subject><subject>Substance-Related Disorders - urine</subject><subject>Toxicology</subject><subject>Treatment Outcome</subject><issn>0002-953X</issn><issn>1535-7228</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>K30</sourceid><recordid>eNp1kEFr3DAQRkVo2G42ueZWME1vxa5GsmzrGJY0DQT2kkBvYmyPWS9rSZW8h_z7aNkl9NCehmHezDc8xm6BFwB19QN3vgAFRV0AF-qCLUFJlddCNJ_YknMucq3k78_sKsZdarmsxYItGg5cKr1km7WbPIYxOpu5IWsPPpB1wW9HSxnaPpto3mLvUjfabN5SNgfCeSI7H3nnRzf2WU-ebE-2o2t2OeA-0s25rtjrz4eX9a_8efP4tL5_zrGU5ZxTV_dQQVtJ3lALWrRCVoBKQ4uiJtGUqKTQehCNBEGtRM2V7GFoRYcywSv29XTXB_fnQHE2O3cINkUaIXipGgCdoLv_QSCBVyJl1IkqTlQXXIyBBuPDOGF4M8DN0bFJjk1ybGpzdJwWvpzPHtqJ-g_8LDXNv53nGDvcDwFtN8YPrIRKc33M_X7C0Pvxr8_-HfoOUQKQbA</recordid><startdate>19940701</startdate><enddate>19940701</enddate><creator>STRAIN, E. C</creator><creator>STITZER, M. L</creator><creator>LIEBSON, I. A</creator><creator>BIGELOW, G. E</creator><general>American Psychiatric Publishing</general><general>American Psychiatric Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>HAWNG</scope><scope>HBMBR</scope><scope>IBDFT</scope><scope>K30</scope><scope>PAAUG</scope><scope>PAWHS</scope><scope>PAWZZ</scope><scope>PAXOH</scope><scope>PBHAV</scope><scope>PBQSW</scope><scope>PBYQZ</scope><scope>PCIWU</scope><scope>PCMID</scope><scope>PCZJX</scope><scope>PDGRG</scope><scope>PDWWI</scope><scope>PETMR</scope><scope>PFVGT</scope><scope>PGXDX</scope><scope>PIHIL</scope><scope>PISVA</scope><scope>PJCTQ</scope><scope>PJTMS</scope><scope>PLCHJ</scope><scope>PMHAD</scope><scope>PNQDJ</scope><scope>POUND</scope><scope>PPLAD</scope><scope>PQAPC</scope><scope>PQCAN</scope><scope>PQCMW</scope><scope>PQEME</scope><scope>PQHKH</scope><scope>PQMID</scope><scope>PQNCT</scope><scope>PQNET</scope><scope>PQSCT</scope><scope>PQSET</scope><scope>PSVJG</scope><scope>PVMQY</scope><scope>PZGFC</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>19940701</creationdate><title>Comparison of buprenorphine and methadone in the treatment of opioid dependence</title><author>STRAIN, E. C ; STITZER, M. L ; LIEBSON, I. A ; BIGELOW, G. E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a434t-ec7d161b6308eb192b2361a591ba27e284a53299f28312eb3a9053d1fb2ca3b23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Administration, Oral</topic><topic>Administration, Sublingual</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Buprenorphine - administration & dosage</topic><topic>Buprenorphine - therapeutic use</topic><topic>Cocaine - urine</topic><topic>Comorbidity</topic><topic>Double-Blind Method</topic><topic>Drug addictions</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Heroin</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methadone - administration & dosage</topic><topic>Methadone - therapeutic use</topic><topic>Middle Aged</topic><topic>Opioid-Related Disorders - drug therapy</topic><topic>Opioid-Related Disorders - epidemiology</topic><topic>Opioid-Related Disorders - rehabilitation</topic><topic>Patient Compliance</topic><topic>Psychiatry</topic><topic>Substance Abuse Detection</topic><topic>Substance abuse treatment</topic><topic>Substance-Related Disorders - epidemiology</topic><topic>Substance-Related Disorders - urine</topic><topic>Toxicology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>STRAIN, E. C</creatorcontrib><creatorcontrib>STITZER, M. L</creatorcontrib><creatorcontrib>LIEBSON, I. A</creatorcontrib><creatorcontrib>BIGELOW, G. E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Periodicals Index Online Segment 13</collection><collection>Periodicals Index Online Segment 14</collection><collection>Periodicals Index Online Segment 27</collection><collection>Periodicals Index Online</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - West</collection><collection>Primary Sources Access (Plan D) - International</collection><collection>Primary Sources Access & Build (Plan A) - MEA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Midwest</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Northeast</collection><collection>Primary Sources Access (Plan D) - Southeast</collection><collection>Primary Sources Access (Plan D) - North Central</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Southeast</collection><collection>Primary Sources Access (Plan D) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - UK / I</collection><collection>Primary Sources Access (Plan D) - Canada</collection><collection>Primary Sources Access (Plan D) - EMEALA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - North Central</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - International</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - International</collection><collection>Primary Sources Access (Plan D) - West</collection><collection>Periodicals Index Online Segments 1-50</collection><collection>Primary Sources Access (Plan D) - APAC</collection><collection>Primary Sources Access (Plan D) - Midwest</collection><collection>Primary Sources Access (Plan D) - MEA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Canada</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - UK / I</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - EMEALA</collection><collection>Primary Sources Access & Build (Plan A) - APAC</collection><collection>Primary Sources Access & Build (Plan A) - Canada</collection><collection>Primary Sources Access & Build (Plan A) - West</collection><collection>Primary Sources Access & Build (Plan A) - EMEALA</collection><collection>Primary Sources Access (Plan D) - Northeast</collection><collection>Primary Sources Access & Build (Plan A) - Midwest</collection><collection>Primary Sources Access & Build (Plan A) - North Central</collection><collection>Primary Sources Access & Build (Plan A) - Northeast</collection><collection>Primary Sources Access & Build (Plan A) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - Southeast</collection><collection>Primary Sources Access (Plan D) - UK / I</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - APAC</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - MEA</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>The American journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>STRAIN, E. C</au><au>STITZER, M. L</au><au>LIEBSON, I. A</au><au>BIGELOW, G. E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of buprenorphine and methadone in the treatment of opioid dependence</atitle><jtitle>The American journal of psychiatry</jtitle><addtitle>Am J Psychiatry</addtitle><date>1994-07-01</date><risdate>1994</risdate><volume>151</volume><issue>7</issue><spage>1025</spage><epage>1030</epage><pages>1025-1030</pages><issn>0002-953X</issn><eissn>1535-7228</eissn><coden>AJPSAO</coden><abstract>OBJECTIVE: This study compared the efficacy of buprenorphine and
methadone in the treatment of opioid dependence. METHOD: Participants (N =
164) were relatively treatment-naive, opioid-dependent applicants to a
26-week treatment program who were randomly assigned to either methadone or
buprenorphine treatment. Dosing was double-blind and double-dummy. Patients
were stabilized on a regimen of either methadone, 50 mg, or buprenorphine,
8 mg, with dose changes possible through week 16 of treatment. Urine
samples were collected three times a week, and weekly counseling was
provided. RESULTS: Buprenorphine (mean dose = 8.9 mg/day) and methadone
(mean dose = 54 mg/day) were equally effective in sustaining retention in
treatment, compliance with medication, and counseling regimens. In both
groups, 56% of patients remained in treatment through the 16-week flexible
dosing period. Overall opioid-positive urine sample rates were 55% and 47%
for buprenorphine and methadone groups, respectively; cocaine-positive
urine sample rates were 70% and 58%. Evidence was obtained for the
effectiveness of dose increases in suppressing opioid, but not cocaine, use
among those who received dose increases. CONCLUSIONS: The results of this
study provide further support for the utility of buprenorphine as a new
medication in the treatment of opioid dependence and demonstrate efficacy
equivalent to that of methadone when used during a clinically guided
flexible dosing procedure.</abstract><cop>Washington, DC</cop><pub>American Psychiatric Publishing</pub><pmid>8010359</pmid><doi>10.1176/ajp.151.7.1025</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-953X |
| ispartof | The American journal of psychiatry, 1994-07, Vol.151 (7), p.1025-1030 |
| issn | 0002-953X 1535-7228 |
| language | eng |
| recordid | cdi_proquest_journals_220458119 |
| source | MEDLINE; Psychiatry Legacy Collection Online Journals 1844-1996; Periodicals Index Online |
| subjects | Administration, Oral Administration, Sublingual Adult Biological and medical sciences Buprenorphine - administration & dosage Buprenorphine - therapeutic use Cocaine - urine Comorbidity Double-Blind Method Drug addictions Drug therapy Female Heroin Humans Male Medical sciences Methadone - administration & dosage Methadone - therapeutic use Middle Aged Opioid-Related Disorders - drug therapy Opioid-Related Disorders - epidemiology Opioid-Related Disorders - rehabilitation Patient Compliance Psychiatry Substance Abuse Detection Substance abuse treatment Substance-Related Disorders - epidemiology Substance-Related Disorders - urine Toxicology Treatment Outcome |
| title | Comparison of buprenorphine and methadone in the treatment of opioid dependence |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T15%3A29%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20buprenorphine%20and%20methadone%20in%20the%20treatment%20of%20opioid%20dependence&rft.jtitle=The%20American%20journal%20of%20psychiatry&rft.au=STRAIN,%20E.%20C&rft.date=1994-07-01&rft.volume=151&rft.issue=7&rft.spage=1025&rft.epage=1030&rft.pages=1025-1030&rft.issn=0002-953X&rft.eissn=1535-7228&rft.coden=AJPSAO&rft_id=info:doi/10.1176/ajp.151.7.1025&rft_dat=%3Cproquest_cross%3E1310625327%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1310625327&rft_id=info:pmid/8010359&rfr_iscdi=true |